| | Power your data-science drug discovery Introducing the QIAGEN Biomedical Knowledge Base. The first expertly curated knowledge base that comes from high-quality manually curated content with granularity and causality that spans multiple domains. Learn more |
Novartis CEO: Leqvio, Pluvicto off to solid starts, but blockbuster sales will take time Medtronic finds new medical, scientific chief in current research and regulatory leader Mauri After a down first quarter, investors question why UHS isn't adjusting its 2022 guidance Abiomed implants first patient with long-term, removable heart pump After Biohaven stopped teasing Nurtec's quarterly performance, should investors be worried? Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder Centene unveils refresh of its Office of the CEO After phase 2 flop, BerGenBio posts new data on COVID-19 prospect Lawmakers ask FDA to lay out plans for reviewing COVID vaccines for young children Biofourmis banks $300M megaround to fuel its growth in remote care, potential M&A deals Pfizer-Valneva's Lyme disease vaccine performs even better in children Intel lends its deep learning AI to DiA Imaging’s heart ultrasound analysis tech Featured Story | By Angus Liu Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to more than $2 billion in sales each. read more |
| |
|---|
|
Top Stories By Andrea Park To replace Richard Kuntz, its outgoing chief medical and scientific officer, Medtronic looked inward. read more By Dave Muoio An ongoing workforce shortage challenged UHS' acute care hospitals and, to a greater extent, its behavioral care facilities, leading the system to miss its internal Q1 earnings goal by 6%. read more By Conor Hale Abiomed has treated its first patient with its minimally invasive heart pump designed to serve as a “bridge-to-recovery” for people suffering from severe heart failure. read more By Angus Liu Biohaven Pharmaceuticals has been offering early peeks at the performance of its closely watched migraine drug launch since the fourth quarter of 2020. So, when the company recently stopped the practice of issuing preliminary results, investors started to worry. read more By Gabrielle Masson Amid chaos comes good news—Editas Medicine has received rare pediatric disease designation from the FDA for its gene-edited medicine EDIT-301 to treat beta thalassemia. read more By Paige Minemyer Centene posted $849 million in profit for the first quarter, up 21% year over year. Revenue leapt even more—by 24%—in CEO Sarah London's first earnings report on the job. read more By Nick Paul Taylor The effort to establish bemcentinib as a COVID-19 drug continues. Eleven months after failing a phase 2 trial, the Danish biotech has shared data from a second, smaller trial that linked the drug to significant changes. read more By Zoey Becker Congress's COVID-19 committee is requesting a scientific explanation for a perceived delay by the FDA in reviewing Moderna's mRNA vaccine in young children. read more By Heather Landi Three years ago, technology startup Biofourmis raised $10 million in total funding to build out its virtual care and digital therapeutics business. This week, the virtual care and digital medicine-focused company announced a massive $300 million cash injection to fuel its growth. read more By Annalee Armstrong Pfizer and Valneva’s Lyme disease vaccine worked even better in children than adults, leading the partners to add this population to a late-stage test beginning in the third quarter. read more By Andrea Park Artificial intelligence developer DiA Imaging Analysis has a fever, and the only prescription is more AI. read more |
